Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Autoimmune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Autoimmune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France; Centre d'Etude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours, France.
Mol Immunol. 2021 Jul;135:147-164. doi: 10.1016/j.molimm.2021.04.010. Epub 2021 Apr 23.
Respiratory pathogens represent a great burden for humanity and a potential source of new pandemics, as illustrated by the recent emergence of coronavirus disease 2019 (COVID-19). In recent decades, biotechnological advances have led to the development of numerous innovative therapeutic molecules and vaccine immunogens. However, we still lack effective treatments and vaccines against many respiratory pathogens. More than ever, there is a need for a fast, predictive, preclinical pipeline, to keep pace with emerging diseases. Animal models are key for the preclinical development of disease management strategies. The predictive value of these models depends on their ability to reproduce the features of the human disease, the mode of transmission of the infectious agent and the availability of technologies for monitoring infection. This review focuses on the use of non-human primates as relevant preclinical models for the development of prevention and treatment for human respiratory infections.
呼吸道病原体对人类构成了巨大的负担，也是新出现的大流行病的潜在来源，正如最近出现的 2019 年冠状病毒病（COVID-19）所表明的那样。近几十年来，生物技术的进步导致了许多创新治疗分子和疫苗免疫原的发展。然而，我们仍然缺乏针对许多呼吸道病原体的有效治疗方法和疫苗。我们比以往任何时候都更需要一个快速、预测性的临床前管道，以跟上新出现的疾病的步伐。动物模型是疾病管理策略临床前开发的关键。这些模型的预测价值取决于它们复制人类疾病特征、传染性病原体传播方式以及监测感染技术可用性的能力。这篇综述重点介绍了使用非人类灵长类动物作为相关临床前模型，用于开发预防和治疗人类呼吸道感染的方法。
